CHEMORADIOTHERAPY FOR RECTAL CANCER IN THE DISTAL RECTUMFOLLOWED BY ORGAN-SPARING TRANSANAL ENDOSCOPICMICROSURGERY

niversity Medical Centre Nijmegen0 个研究点目标入组 55 人开始时间: 2010年4月19日最近更新: 2021年12月21日

适应症

试验速览

暂无简介。

•Patients (aged >18 years) with histological proven adenocarcinoma of the distal part of the rectum (below 10 cm) without signs of distant metastases.
•T1-3 tumor without lymph nodes > 5 mm at CT, MRI and endoanal ultrasound.
•ANC > 1.5 x 109/l.
•Thrombocytes > 100 x 109/l.
•Creatinin clearance >50ml/min (according to the Cockcroft-Gault formule)
•Total serum bilirubin < 24 mmol/l or below <1.5 times the upper limit of the normal.
•ASAT,ALAT: up to 5 times the upper limit.
•Colonoscopy, colonography or virtual colonoscopy should exclude synchronous colorectal lesions in other parts of the colon.
•ECOG performance score 0-2.
•Fertile women should have adequate birthcontrol during treatment.
•Mental/physical/geographical ability to undergo treatment and follow-up.
•Written informed consent (Dutch language).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients with Grade 1-2 T1 tumors (can be treated with TEM surgery without chemoradiation therapy)
•Patients with circular rectal tumor or tumors who are by other means unacceptable for TEM surgery (e.g. intra-analtumors).
•Patients with faecal incontinence prior to the diagnosis of rectal cancer (complaints of soiling due to the tumor will not be an exclusion criterium).
•Severe uncontrollable medical or neurological disease.
•Patients with secondary prognosis determining malignancies.
•Patients who have been treated with radiotherapy on the pelvis.
•Use of Warfarin.
•Uncontrolled active infection, compromised immune status, psychosis, or CNS disease.
•Pregnant or lactating women.
•Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (= 6 months prior to randomisation), myocardial infarction (= 6 months prior to randomisation), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication.
•Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of Capecitabine or patients at high risk for treatment complications.
•History or evidence upon physical examination of CNS disease unless adequately treated (e.g., seizure not controlled with standard medical therapy).

发起方

niversity Medical Centre Nijmegen